Retrieval of Hepatitis C Patients Lost to Follow-up
NCT04153708 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 352
Last updated 2021-04-30
Summary
The main purpose of the study is to compare the efficacy of two strategies aimed to rescue patients lost to follow-up with active infection or with positive HCV antibodies without RNA request to complete evaluation and prescription of treatment in cases of chronic infection. After patient identification from data files of laboratory and microbiology charts, patients will be randomized to: a) phone call, and b) invitation letter, both of two strategies including a scheduled appointment with the hepatologist.
Conditions
- Hepatitis C
Interventions
- BEHAVIORAL
-
Retrieval patients lost to follow-up with positive HCV antibodies without RNA request or positive RNA by phone call.
Patients assigned to strategy 1 will be called to schedule an appointment with the hepatologist over a period of 14 days.
- BEHAVIORAL
-
Retrieval patients lost to follow-up with positive HCV antibodies without RNA request or positive RNA by mail letter
Patients assigned to strategy 2 will receive an invitation letter with an appointment with the hepatologist over a period of 14 days.
Sponsors & Collaborators
-
University of La Laguna
lead OTHER
Principal Investigators
-
Enrique Quintero Carrion, MD · Hospital Universitario de Canarias
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-11-03
- Primary Completion
- 2021-09-01
- Completion
- 2021-09-01
Countries
- Spain
Study Locations
More Related Trials
-
Efficacy Study of New Therapeutic Schedules in Naive Hepatitis C Virus (HCV) Patients Infected With Genotype 3 (HCV-3)
NCT01121705 ·Status: COMPLETED ·Phase: PHASE3
-
A Retrospective Study to Assess the Impact of the Use of Interferon in Patients With Chronic Hepatitis C (DECISION)
NCT01280656 ·Status: COMPLETED
-
24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C
NCT01517308 ·Status: WITHDRAWN ·Phase: PHASE3
-
Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C
NCT01447394 ·Status: WITHDRAWN ·Phase: PHASE3
-
Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol (Study P05269)(COMPLETED)
NCT00724373 ·Status: COMPLETED
-
Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C
NCT01754974 ·Status: COMPLETED ·Phase: PHASE3
-
Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV
NCT01310205 ·Status: COMPLETED
-
Compliance of HCV Genotype 1 Infected Patients Receiving PegIntron/Rebetol and a Patient Assistance Program (Study P04671)
NCT00728494 ·Status: COMPLETED
-
Identification of Viral Variants Involved in the Transmission of Hepatitis C and Characterization of Antigenic and Functional Properties of Their Envelope Glycoproteins
NCT02574884 ·Status: COMPLETED ·Phase: NA
-
Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed)
NCT00725842 ·Status: TERMINATED
-
Antiviral Therapy in Decompensated Hepatitis C Virus (HCV) Cirrhosis
NCT00301509 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study Investigating Immunological Effects of Treatment for Chronic Hepatitis C Patients.
NCT00422838 ·Status: COMPLETED
-
A Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection
NCT00217139 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacogenomics Study on IL28B Genetic Variants in Italian Patients With HCV Infection naïve to Treatment.
NCT01437969 ·Status: COMPLETED
-
Study to Investigate Tolerability and Efficacy of MK5172 / MK8742 Without Ribavirin for 12 Weeks in Patients With Chronic HCV G1b Infection With Compensated Cirrhosis
NCT02732405 ·Status: UNKNOWN ·Phase: PHASE3
-
Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice.
NCT01195181 ·Status: COMPLETED ·Phase: PHASE4
-
High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV
NCT00381953 ·Status: COMPLETED ·Phase: PHASE3
-
A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies
NCT00872196 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
NCT01544920 ·Status: COMPLETED ·Phase: PHASE3
-
3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study
NCT02465203 ·Status: TERMINATED ·Phase: PHASE3
-
A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy
NCT01058512 ·Status: COMPLETED ·Phase: PHASE2
-
GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype
NCT01384383 ·Status: TERMINATED ·Phase: PHASE2
-
Program of Screening, Prevention and Elimination of Hepatitis C in Penitentiary Institutions in Cantabria (JAILFREE-C)
NCT02768961 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV Patients
NCT01055821 ·Status: COMPLETED ·Phase: PHASE2
-
Multicenter Study Evaluating 12 Versus 24 Weeks Therapy With Peginterferon and Ribavirin for Hepatitis C Virus (HCV) Genotype 2 or 3
NCT00143000 ·Status: COMPLETED ·Phase: PHASE4